When we look at the North American or European market, nearly 20% of people must follow a second-line treatment. But there is another problem: we should have never chosen the first-line treatment we chose from the beginning. It was well intentioned in the beginning, but today we realize how toxic this treatment is. When a patient follows this treatment for two or three years, the toxicity level is very significant. We will now have to replace the most commonly used molecule, which is available around the world, with something safer.
On October 21st, 2010. See this statement in context.